Novo Holdings Rallybio Corp Transaction History

Novo Holdings

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.91 - $4.39 $802,463 - $1.84 Million	-420,138 Reduced 19.2%	1,767,861 $4.23 Million
Q2 2023 Aug 14, 2023	SELL	$4.31 - $8.89 $353,898 - $729,966	-82,111 Reduced 3.62%	2,187,999 $12.4 Million
Q1 2023 May 15, 2023	SELL	$4.37 - $8.75 $113,169 - $226,598	-25,897 Reduced 1.13%	2,270,110 $13 Million
Q4 2022 Feb 14, 2023	BUY	$4.67 - $14.86 $7.78 Million - $24.7 Million	1,665,086 Added 263.91%	2,296,007 $15.1 Million
Q3 2022 Nov 14, 2022	SELL	$7.54 - $14.56 $106,314 - $205,296	-14,100 Reduced 2.19%	630,921 $9.13 Million
Q2 2022 Aug 15, 2022	BUY	$6.26 - $13.65 $1.31 Million - $2.85 Million	209,077 Added 47.96%	645,021 $4.87 Million
Q1 2022 May 16, 2022	BUY	$6.91 - $15.04 $3.01 Million - $6.56 Million	435,944 New	435,944 $3.04 Million

31.9M

Ticker RLYB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,132,000
Market Cap $30.5M
Description
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...

Get notified when there are updates to the investment portfolio of Novo Holdings, based on Form 13F filings with the SEC.

Stay updated on Novo Holdings with notifications on news.